Celea Therapeutics is dedicated to advancing transformative treatments for people with serious respiratory diseases. Drawn from the Latin word for "sky," our name reflects our mission: to rise above the status quo and deliver therapies that change lives.
Our lead program, deupirfenidone (LYT-100), is in Phase 3 development with the potential to set a new standard of care for idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases.
Celea was founded by PureTech Health plc (LSE: PRTC), a biotherapeutics company dedicated to giving life to science.
EXPLORE MORE
Celea brings together an accomplished team with extensive experience advancing pulmonary therapeutics. In partnership with physicians and patient advocacy organizations, we are committed to developing deupirfenidone as a new standard of care for people living with idiopathic pulmonary fibrosis.
